| Company Name: |
Energy Chemical |
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing@energy-chemical.com |
|
| | 8-(4-Chlorophenylthio)-2',O-methyladenosine 3',5'-cyclic monophosphate sodium salt Basic information |
| Product Name: | 8-(4-Chlorophenylthio)-2',O-methyladenosine 3',5'-cyclic monophosphate sodium salt | | Synonyms: | ADENOSINE 3',5'-CYCLIC MONOPHOSPHATE, 8-(4-CHLOROPHENYLTHIO)-2'-O-METHYL-, SODIUM SALT;8-PCPT-2''-O-ME-CAMP SODIUM SALT;8CPT-2ME-CAMP, SODIUM SALT;8-CPT-2'-O-ME CAMP NA;CAMP, 8-CPT-2'-O-ME, NA;8-[(4-Chlorophenyl)thio]-2'-O-methyladenosine cyclic 3',5'-(hydrogen phosphate);Adenosine, 8-[(4-chlorophenyl)thio]-2'-O-methyl-, cyclic 3',5'-(hydrogen phosphate);8-(4-Chlorophenylthio)-2&rsquo | | CAS: | 510774-50-2 | | MF: | C17H17ClN5O6PS | | MW: | 485.84 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | 8-(4-Chlorophenylthio)-2',O-methyladenosine 3',5'-cyclic monophosphate sodium salt Chemical Properties |
| Boiling point | 748.9±70.0 °C(Predicted) | | density | 1.95±0.1 g/cm3(Predicted) | | storage temp. | Desiccate at -20°C | | solubility | water: 10 mg/mL | | form | White to off-white crystalline powder. | | pka | 0.92±0.60(Predicted) | | Water Solubility | water: 10mg/mL |
| WGK Germany | WGK 1 | | Storage Class | 11 - Combustible Solids |
| | 8-(4-Chlorophenylthio)-2',O-methyladenosine 3',5'-cyclic monophosphate sodium salt Usage And Synthesis |
| Uses | 8-(4-Chlorophenylthio)-2''-O-methyladenosine 3'',5''-cyclic Monophosphate sodium salt is an activator of the Epac cAMP receptor. It can be used in biological study of interaction between TCL1 and Epac1 in activation of Akt kinases in plasma membranes and nuclei of 8-CPT-2-O-Me-cAMP-stimulated macrophages | | Biological Activity | Selective activator of Epac, the cAMP-sensitive guanine nucleotide-exchange factor for Rap1 and Rap2. Activates Epac1 (EC 50 = 2.2 mM), but not PKA (EC 50 > 10 mM). Stimulates Epac-mediated Ca 2+ -mediated Ca 2+ release in pancreatic b-cells in vitro . | | in vivo | 8-CPT-2'-O-Me-cAMP (2.05μM; 1 μL; intravitreal injection) inhibits development of choroidal neovascular lesions in a laser-injury model[1]. | Animal Model: | Wild type (WT) C57/Bl6 mice (choroidal neovascularization (CNV) model) [1] | | Dosage: | 2.05μM; 1 μL | | Administration: | Intravitreal injection | | Result: | Induced a slight increase in F-actin localization to the cell periphery, and reorganized cell junctions to a more linear shape, dose-dependent decreased in CNV volume, increased Rap1 activity in isolated RPE/choroids. |
|
| | 8-(4-Chlorophenylthio)-2',O-methyladenosine 3',5'-cyclic monophosphate sodium salt Preparation Products And Raw materials |
|